IL17A and psoriasis: During 2021–2022 several dermatological societies have updated their clinical guidelines considering the approval of new molecules by drug regulatory agencies.27, 28, 29, 30, 31, 32, 33 Guidelines recognize anti-IL-23 and anti-IL-17 drugs as part of the first-line treatment profile for psoriasis management.